Activinsights Joins Prestigious UK Digital Health Playbook

We are delighted to share the exciting news that Activinsights has earned its place in the esteemed Department for Business and Trade's newly enhanced Digital Health Playbook!

About the Digital Health Playbook:

Featuring a robust lineup of over 180 UK innovators and exporters, the Digital Health Playbook serves as the ultimate resource hub for healthtech innovation. This inclusive platform showcases specialists with vast expertise in delivering advanced patient care, insights and analysis, core infrastructure, and self-care solutions.

Rigorous Selection Process:

We underwent a meticulous selection process, our inclusion in the Playbook is a testament to our collaborative excellence within healthcare, our responsiveness, and our role in representing the UK's journey in digital health, particularly within the NHS. The Playbook undergoes regular reviews to ensure its cutting-edge relevance.

Discover Activinsights:

Find us under "Driving insights and analysis" within the Playbook if you seek a partner proficient in delivering intelligence derived from healthcare data.

How Activinsights Stands Out:

As a distinguished digital health company, we specialise in objectively measuring physical behaviours and lifestyles. Our technologies, deployed worldwide in clinical trials, health management, and research markets, provide accurate and continuous monitoring of lifestyle beyond clinical settings. Key features include:

Key Facts:

Join our journey in shaping the future of digital health! Let's collaborate on upcoming research or clinical trials—contact us today for impactful partnerships.

Your personal information will be processed & stored in line with our Privacy Information Policy

Activinsights Feature in the DIT UK Digital Health Playbook 2023

Activinsights Feature in the Department for International Trade's 2023 UK Digital Health Playbook

By Dr Raghbir Bains, Commercial Director

Thrilled to see Activinsights Ltd featured in the new Department for International Trade (DIT) #UKDigitalHealth Playbook - 2023 Edition.

Digital Health is rightly seen as the answer to many of the challenges facing global healthcare.  The role of digital technology in realising the dream of accessible, affordable, and sustainable care has grown across the entire range of health economies in not only serving current needs, but in building the basis for the healthcare of the future: personalised, digital by default and truly patient centric.

The innovations highlighted in the Playbook can offer support to healthcare in a variety of ways from solutions such as from Activinsights to support people at home with self-care apps and wearable technology which all will help transform healthcare, particularly as the Covid-19 pandemic has demonstrated the tremendous potential of digital transformation.

Activinsights is featured under the Remote and Virtual Care category, the wearable technology enabling to monitor patients remotely and maintaining the ability to act fast. These digital technology solutions are interventions that can be initiated by a physician and linked to a clinical care pathway. It differs from self-care solutions, which are driven by the empowered citizen. This a UK solution which allows healthcare providers to reduce risk, cost, and readmissions and demands on your health system, while improving the patient experience, by empowering teams to safely monitor, manage and engage patients at home.

Activinsights is a digital health company that specialises in the objective measurement of physical behaviours and lifestyle. Our technologies are used worldwide within the clinical trials, health management and research markets to provide accurate and continuous monitoring of lifestyle outside of the clinic environment. We develop novel health measures from data collected by our own professional wearables within a scalable global and secure infrastructure.

Time for Digital Selection Biomarkers

Time for Digital Selection Biomarkers

By Arthur Combs, Senior Clinical Advisor

Did you know that the use of selection biomarkers in clinical development improves the success rate in every phase (I-III)? And that use of selection biomarkers improves the overall success from Phase I through regulatory approval more than 3-fold? Examples include using tumour markers to select patients for cancer therapy trials or knowing the ejection fraction (EF) for heart failure patients since those with preserved EF behave and respond differently from those with reduced EF.

Unfortunately, many patient selection processes are dependent on an overarching inclusive diagnosis, a subjective rating scale or both. These are opportunities for the use of actigraphy to objectively and precisely characterize the functional status of study candidates. Oncology, neurodegenerative diseases, and many others depend on subjective rating scales for patient selection. For example, oncology subjects are often selected based on an the Eastern Cooperative Oncology Score (ECOG) score.

This score characterizes the ability of a subject to perform daily activities and any restrictions in place. Clinical development studies often select ECOG subjects judged to be ECOG 0, 1 or 2 to ensure that a subject is able to tolerate the study therapy. But performance and functional data from wearable technologies show that what were thought to be homogeneous [ECOG] groups with a given score, in actuality are groups that demonstrate significantly heterogeneity in their total activity, step counts, stairs climbed and other actigraphy metrics.

It is time to consider true functional status as a digital biomarker of patients’ suitability for a given trial. Given the benefit of using selection biomarkers in clinical development, the development and application of digital selection biomarkers through use of wearable sensors and functional assessment in real-world settings could significantly improve both the efficiency and success of clinical development trials. This is especially true in conditions where the selection of study subjects is based on broad diagnosis, subjective classification, surveys and patient-reported outcomes.

Digital Biomarkers: The Future is Here!

Digital Biomarkers: The Future is Here!

By Bill Hogan, CEO

A quick visit to the US National Library of Medicine and specifically and you can read the following…

“In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the research team. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants’ behaviour such as diet. Clinical trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients, or to no intervention. Some clinical trials compare interventions that are already available to each other.

When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives. Investigators try to determine the safety and efficacy of the intervention by measuring certain outcomes in the participants.”

So far, so good! Have you ever wondered though how detailed, thorough, or relevant is the data generated as described above. Certainly, the recent global pandemic has seen a very significant shift towards decentralised and virtual clinical trials. Under-pinning these shifts has been the proliferation of hardware and software that enables data collection remotely.

Frequent, objective and sensitive assessments are critical to measuring health trends and determine the efficacy of new therapeutics. Traditionally, intermittent clinical observations at long intervals were the standard accepted practice. Throughout the pandemic we saw increased validation and verification of continuous monitoring. Wearable accelerometers can continuously capture data to assess health and today we are seeing the rise of digital biomarkers as a result.

Real-world Raw Data

Real-world data derived from objective raw data is key to this continued development. Not all devices will deliver raw data! The ability to realise primary and secondary digital clinical end-points is built upon the availability of raw data and ability to translate the data analytics into digital clinical end points and health biomarkers.

The Digital Medicine Society (DiMe) is a global non-profit organisation and a base for the global digital medicine community. Their aim is to drive scientific progress and broad acceptance in digital medicine to enhance public health. We are about to work closely with DiMe on a project to define an optimized set of core digital clinical measures that address patient, care-partner, and clinical unmet need for aspects of health that span multiple therapeutic areas in physical activity - a domain where digital clinical measurement capabilities are already well advanced.

We are very much looking forward to the next phase of our collaboration with DiMe.

Digital Measures - Is it Validated? Part Two

Digital Measures - Is it Validated?
Part Two

If you missed it, you can read part one here.


By Stephanie Sargeant, Commercial Manager

We know the use and impact of digital measures, biomarkers and endpoints continues to explode. The terminology itself can be confusing and difficult to navigate. Depending on an individual’s involvement in the trial, stakeholders may still not always be making the correlation when selecting wearables within trials, for the importance of thinking the trial data through to the end.

Selection teams may get deterred with wanting to include every sensor type because it’s available at the cost of long-term wear and validated data - topics we continue to educate on within clinical trials. Yes, adherence and compliance are vital, but when we cut to the chase, the technology selected is a means to an end – it’s all about the data! In selecting the appropriate technology it’s therefore key to consider:

Asking about validation can be a loaded question, the industry needs to be clear about what it means and is trying to achieve here - we often see a disparity in the expectations of study design teams with the readiness of off-the-shelf, validated algorithms. The sector is evolving rapidly in terms of the implementation of digital measures within clinical trials and open-source algorithm development, along with the approach from regulators such as the MHRA and FDA, who have recently released guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. When combined with the nuances of different population groups, therapeutic areas and digital measures are considered – there’s still a long journey to go on.

In the meantime, Activinsights remains committed to leading the way in objective digital health measurement. Keeping it simple and accessible with a clear pathway to validation, alongside ongoing algorithm development for relevant digital measures across therapeutic areas. We’ve identified over 150 digital measures we regularly use in data analysis – watch this space for more information coming soon here!

There is a clear route being formed on more readily available, validated digital measures using ‘off-the-shelf algorithms’ alongside the need for ongoing algorithm development to identify novel measures, specific to population groups. This can often be done in parallel to a clinical trial. As digital health measurement experts, it’s our job to support study trial design, scientific and digital biomarker teams with trials co-coordinators to navigate this space. Combining easy deployment, relevant, meaningful and validated digital measures to improve study efficiency and novel insights outside the clinic with remote patient monitoring.

Be patient – as an industry, it’s on its way!



Digital Measures - Is it Validated? Part One

Digital Measures - Is it Validated?
Part One

By Stephanie Sargent, Commercial Manager

It’s often the big question when discussing the data from wearables, and so it should be – ‘is it validated?’

This is vital for several reasons. Study teams need to consider regulators, patient population groups, therapeutic areas and traceability on generating the most accurate and reliable data possible within a clinical trial. So, what is ‘validation’?

The Digital Medicine Society (DiME) provides a useful definition and tool, known as the V3 framework – which encompasses verification, analytical validation, and clinical validation (V3). The three-component V3 framework combines established practices from both software and clinical development to establish the shared foundation for evaluating whether digital clinical measures are fit-for-purpose.

At Activinsights, we are proud of over a decade’s heritage in public health research across 200+ global institutions, reaching 40+ countries. Our focus in the last couple of years has been to bring learnings across from the research sector into the clinical trials landscape for relevant and meaningful digital measures for both the patient and clinician – where there are now 100 + clinical trials operating with Activinsights’ technologies across 20+ therapeutic areas.

A breadth of knowledge around validation in different population groups and digital measures can be translated into digital clinical measures from peer-reviewed public health research. An example includes Activinsights' supporting metrics in the objective monitoring of fidgeting behaviours, where early work has been done in children with Autism Spectrum Disorder. This knowledge in algorithm development may also be relevant for dementia trials, as an increase in night-time wandering behaviours has been identified as a biomarker for disease progression. This is where continuous remote monitoring comes into its own for valuable insights on objective lifestyle and disease progression alongside drug efficacy, outside of clinic visits.

Throughout the trial, it remains key that collecting objective data is unobtrusive and of low participant burden. Another example of the benefit of algorithm development from peer-reviewed, open-source raw data formats is understanding steps in more detail for specific therapeutic areas. Steps appears to be a commonly requested measure within clinical trials, likely because it’s easily interpretable across both clinical and patient population groups.

So, the client says: ‘Do you have a step measure available and is validated?’

Activinsights' reply: ‘Yes…’

However, it’s not a one-size fits all approach. We have validated steps measures; but ultimately it depends on the population group and therapeutic area we’re talking about. Not all steps are measured the same. A healthy child may take the same number of total steps as a Parkinson’s patient, but how often and when, along with the gait information around those steps could be dramatically different. It demonstrates how inextricably linked algorithm development and validation are, and it is not as simple as selecting an ‘off-the-shelf algorithm’ that is validated for a one-size-fits-all approach within clinical trials.

DiME have recently highlighted the challenge that different measures presents across the clinical trials industry, and the need for a core set of digital clinical measures that are accepted with evidence as a starting point. It highlights the importance of removing vendor biases with black-box algorithms, hence the trend of working in an open-source environment with reproducible raw data sets, like the GENEActiv, to drive the sector forward.